STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BBIO Form 4 shows CEO Kumar Haldea RSU vesting and trusts

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma (BBIO) Chief Executive Officer and director Kumar Haldea reported routine equity activity on a Form 4 dated 11/16/2025. Several blocks of restricted stock units (RSUs) were converted into common stock as they vested, and a portion of the resulting shares was withheld to cover taxes.

Following these transactions, Haldea directly owns 254,932 shares of BridgeBio common stock. He also reports indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he is a co‑trustee and disclaims beneficial ownership beyond any pecuniary interest. The RSU awards vest quarterly over time as long as he continues serving the company, and the RSUs carry no expiration date.

Positive

  • None.

Negative

  • None.
Insider Kumar Neil
Role Chief Executive Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 33,544 $0.00 --
Exercise Restricted Stock Units 19,599 $0.00 --
Exercise Restricted Stock Units 11,554 $0.00 --
Exercise Common Stock 33,544 $0.00 --
Exercise Common Stock 19,599 $0.00 --
Exercise Common Stock 11,554 $0.00 --
Tax Withholding Common Stock 32,855 $66.39 $2.18M
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 167,720 shares (Direct); Common Stock — 256,634 shares (Direct); Common Stock — 795,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,697 shares of Common Stock underlying the Reporting Person's RSUs. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kumar Neil
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/16/2025 M 33,544 A (1) 256,634 D
Common Stock 11/16/2025 M 19,599 A (1) 276,233 D
Common Stock 11/16/2025 M 11,554 A (1) 287,787 D
Common Stock 11/16/2025 F 32,855(2) D $66.39 254,932 D
Common Stock 795,686 I By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock 4,598,447 I By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 11/16/2025 M 33,544 (4) (4) Common Stock 33,544 $0 167,720 D
Restricted Stock Units (1) 11/16/2025 M 19,599 (5) (5) Common Stock 19,599 $0 176,394 D
Restricted Stock Units (1) 11/16/2025 M 11,554 (6) (6) Common Stock 11,554 $0 150,199 D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,697 shares of Common Stock underlying the Reporting Person's RSUs.
3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
4. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
5. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
6. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Remarks:
/s/ Will Solis, Attorney-in-Fact 11/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BridgeBio Pharma (BBIO) disclose in this Form 4?

The filing reports that CEO and director Kumar Haldea had several blocks of restricted stock units (RSUs) vest on 11/16/2025, converting into BridgeBio common stock, with some shares withheld to cover taxes.

How many BridgeBio (BBIO) shares does CEO Kumar Haldea now hold directly?

After the reported transactions, CEO Kumar Haldea directly owns 254,932 shares of BridgeBio Pharma common stock.

What indirect BridgeBio (BBIO) holdings are reported for Kumar Haldea?

The filing reports 795,686 shares held indirectly through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares held indirectly through the Kumar Haldea Revocable Trust, where he is a co‑trustee.

How were taxes handled on the RSU vesting for BridgeBio (BBIO) CEO?

The Form 4 notes that 32,855 shares of BridgeBio common stock were withheld to satisfy Kumar Haldea’s tax obligations related to the vesting of 64,697 shares underlying his RSUs.

What are the vesting terms of the RSUs reported in this BridgeBio (BBIO) Form 4?

For each RSU grant, 1/16th of the underlying shares vested on a stated May 16 start date (2023, 2024, or 2025), and thereafter 1/16th vests quarterly, subject to Kumar Haldea’s continued service with BridgeBio or its subsidiaries; the RSUs have no expiration date.

Does this BridgeBio (BBIO) Form 4 indicate any open-market stock sale by the CEO?

The reported transactions primarily involve RSU vesting (code M) and share withholding for taxes (code F); the filing does not describe open‑market sales by CEO Kumar Haldea.